Literature DB >> 18173969

Selection and education of patients for inhaled insulin.

Srikanth Bellary1, Anthony H Barnett.   

Abstract

Inhaled insulin is a recent advance in insulin delivery that promises to be an effective alternative to subcutaneous insulin. Several insulin delivery systems are currently in development and the first of these has been approved for clinical use. Inhaled insulin offers greater flexibility and convenience for patients with diabetes and may be particularly useful in those who are reluctant to initiate or intensify insulin treatment. Although promising, potential concerns remain regarding its long-term effects on lungs. Also, excluding certain groups of patients such as smokers and those with respiratory illnesses will restrict its use at present. Lack of familiarity with the technology, especially relating to dose adjustments and inhaler device, is also likely to present fresh challenges. But, careful selection of patients, education, and continued support from health professionals is vital to ensure success with this new technology.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18173969     DOI: 10.1007/s11892-007-0059-6

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  21 in total

Review 1.  Lung dysfunction in diabetes.

Authors:  Michael David Goldman
Journal:  Diabetes Care       Date:  2003-06       Impact factor: 19.112

2.  An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with glibenclamide as adjunctive therapy in patients with type 2 diabetes poorly controlled on metformin.

Authors:  Anthony H Barnett; Manfred Dreyer; Peter Lange; Marjana Serdarevic-Pehar
Journal:  Diabetes Care       Date:  2006-08       Impact factor: 19.112

3.  Injection related anxiety in insulin-treated diabetes.

Authors:  A Zambanini; R B Newson; M Maisey; M D Feher
Journal:  Diabetes Res Clin Pract       Date:  1999-12       Impact factor: 5.602

4.  Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trial.

Authors:  Ralph A DeFronzo; Richard M Bergenstal; William T Cefalu; John Pullman; Sam Lerman; Bruce W Bode; Lawrence S Phillips
Journal:  Diabetes Care       Date:  2005-08       Impact factor: 19.112

5.  Influence of acute upper respiratory tract infection on the absorption of inhaled insulin using the AERx insulin Diabetes Management System.

Authors:  Aidan McElduff; Laurence E Mather; Peter C Kam; Per Clauson
Journal:  Br J Clin Pharmacol       Date:  2005-05       Impact factor: 4.335

6.  Two-year safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 1 diabetes.

Authors:  Jay S Skyler; Lois Jovanovic; Sol Klioze; Joann Reis; William Duggan
Journal:  Diabetes Care       Date:  2007-03       Impact factor: 19.112

7.  The effect of smoking cessation and subsequent resumption on absorption of inhaled insulin.

Authors:  Reinhard H A Becker; Sue Sha; Annke D Frick; Robert J Fountaine
Journal:  Diabetes Care       Date:  2006-02       Impact factor: 19.112

8.  The impact of smoking on inhaled insulin.

Authors:  Anders Himmelmann; Johan Jendle; Anders Mellén; Astrid H Petersen; Ulf L Dahl; Per Wollmer
Journal:  Diabetes Care       Date:  2003-03       Impact factor: 19.112

9.  Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial.

Authors:  Priscilla A Hollander; Lawrence Blonde; Richard Rowe; Adi E Mehta; Joseph L Milburn; Kenneth S Hershon; Jean-Louis Chiasson; Seymour R Levin
Journal:  Diabetes Care       Date:  2004-10       Impact factor: 19.112

10.  Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report.

Authors:  Carol E Koro; Steven J Bowlin; Nancy Bourgeois; Donald O Fedder
Journal:  Diabetes Care       Date:  2004-01       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.